Table 1 Baseline characteristics of correlates population, control population, and cases and noncases among correlates cohort

From: Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

 

ChAdOx1 nCoV-19 correlates population (n = 4,372)

MenACWY control population (n = 4,194)

ChAdOx1 nCoV-19 correlates cohorta

   

Cases (n = 171)

Noncases (n = 1,404)

Age group

18–55 years

3,240 (74.1%)

3,229 (77%)

144 (84.2%)

1,005 (71.6%)

56–69 years

542 (12.4%)

482 (11.5%)

10 (5.8%)

194 (13.8%)

≥70 years

590 (13.5%)

483 (11.5%)

17 (9.9%)

205 (14.6%)

Sex (Female)

2,533 (57.9%)

2,526 (60.2%)

102 (59.6%)

780 (55.6%)

Ethnicity

White

4,036 (92.3%)

3,914 (93.3%)

160 (93.6%)

1,293 (92.1%)

Asian

220 (5.0%)

184 (4.4%)

8 (4.7%)

71 (5.1%)

Black

21 (0.5%)

15 (0.4%)

1 (0.6%)

10 (0.7%)

Otherb

95 (2.2%)

81 (1.9%)

2 (1.2%)

30 (2.1%)

BMI (mean (s.d.))

26.4 (5)

26.5 (5.2)

27 (5.2)

26.5 (5.1)

BMI < 30

3,519 (80.5%)

3,347 (79.8%)

130 (76.0%)

1,124 (80.1%)

BMI ≥ 30

852 (19.5%)

846 (20.2%)

41 (24.0%)

280 (19.9%)

Comorbidities

1,088 (24.9%)

1,032 (24.6%)

44 (25.7%)

360 (25.6%)

Respiratory disease

547 (12.5%)

537 (12.8%)

20 (11.7%)

178 (12.7%)

Cardiovascular disease

572 (13.1%)

514 (12.3%)

24 (14.0%)

192 (13.7%)

Diabetes

99 (2.3%)

85 (2%)

3 (1.8%)

36 (2.6%)

Healthcare worker status

Nonhealthcare worker

1,652 (37.8%)

1,456 (34.7%)

65 (38.0%)

597 (42.5%)

Healthcare worker facing no more than one patient with COVID-19 per day

1,904 (43.6%)

1,938 (46.2%)

74 (43.3%)

587 (41.8%)

Healthcare worker facing at least one patient with COVID-19 per day

816 (18.7%)

800 (19.1%)

32 (18.7%)

220 (15.7%)

Baseline risk probabilitiesc

Mean (s.d.)

0.0786 (0.0303)

0.0794 (0.0296)

0.0824 (0.0283)

0.0774 (0.0306)

Dosage schedule

LD/LD

125 (2.9%)

69 (1.6%)

7 (4.1%)

114 (8.1%)

LD/SD

1,420 (32.5%)

1,361 (32.5%)

46 (26.9%)

320 (22.8%)

SD/SD

2,827 (64.7%)

2,764 (65.9%)

118 (69%)

970 (69.1%)

Prime-boost interval

<6 weeks

1,078 (24.7%)

931 (22.2%)

28 (16.4%)

456 (32.5%)

6–8 weeks

538 (12.3%)

478 (11.4%)

43 (25.1%)

197 (14%)

9–11 weeks

1,158 (26.5%)

1,236 (29.5%)

42 (24.6%)

398 (28.3%)

≥12 weeks

1,598 (36.6%)

1,549 (36.9%)

58 (33.9%)

353 (25.1%)

Length of follow-up (days) from 7 days post PB28 until infection occurred or Feb 28 2021 (median (IQR))

88 (64, 113)

85 (62, 108)

53 (29, 81)

105 (81, 135)

NAAT+ cases

174

333

171

 

Symptomatic

55 (31.6%)

196 (58.9%)

54 (31.6%)

 

Asymptomatic

99 (56.9%)

112 (33.6%)

97 (56.7%)

 

Nonprimary symptomatic

20 (11.5%)

25 (7.5%)

20 (11.7%)

 
  1. BMI, body mass index; LD, low dose; SD, standard dose
  2. aThe correlates cohort is a subset of all eligible participants in the ChAdOx1 nCoV-19 correlates populations who have samples processed for at least one assay.
  3. bOptions included in ‘Other’ are as follows: ‘Mixed’, ‘Other – Free text’, or ‘prefers not to give’.
  4. cThe baseline risk exposure score summarizes predicted probability of having NAAT+ outcome from the risk model developed using the MenACWY Control Population.
Back to article page